Contrasting Dyne Therapeutics (NASDAQ:DYN) and MediWound (NASDAQ:MDWD)

MediWound (NASDAQ:MDWD) and Dyne Therapeutics (NASDAQ:DYN) are both medical companies, but which is the superior stock? We will contrast the two businesses based on the strength of their valuation, analyst recommendations, dividends, earnings, profitability, risk and institutional ownership.

Insider and Institutional Ownership

46.8% of MediWound shares are held by institutional investors. Comparatively, 96.7% of Dyne Therapeutics shares are held by institutional investors. 9.2% of MediWound shares are held by insiders. Comparatively, 14.1% of Dyne Therapeutics shares are held by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock is poised for long-term growth.

Earnings & Valuation

This table compares MediWound and Dyne Therapeutics”s gross revenue, earnings per share and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
MediWound	$16.96 million	12.74	-$23.88 million	($2.10)	-8.00
Dyne Therapeutics	N/A	N/A	-$446.21 million	($3.54)	-5.32

MediWound has higher revenue and earnings than Dyne Therapeutics. MediWound is trading at a lower price-to-earnings ratio than Dyne Therapeutics, indicating that it is currently the more affordable of the two stocks.

Analyst Recommendations

This is a breakdown of current ratings and recommmendations for MediWound and Dyne Therapeutics, as provided by MarketBeat.com.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
MediWound	1	1	3	0	2.40
Dyne Therapeutics	1	2	11	3	2.94

MediWound currently has a consensus target price of $31.67, indicating a potential upside of 88.38%. Dyne Therapeutics has a consensus target price of $35.14, indicating a potential upside of 86.53%. Given MediWound’s higher probable upside, equities analysts plainly believe MediWound is more favorable than Dyne Therapeutics.

Volatility & Risk

MediWound has a beta of 0.15, suggesting that its share price is 85% less volatile than the S&P 500. Comparatively, Dyne Therapeutics has a beta of 1.29, suggesting that its share price is 29% more volatile than the S&P 500.

Profitability

This table compares MediWound and Dyne Therapeutics’ net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
MediWound	-140.80%	-65.79%	-30.16%
Dyne Therapeutics	N/A	-61.46%	-50.94%

Summary

Dyne Therapeutics beats MediWound on 9 of the 14 factors compared between the two stocks.

About MediWound

MediWound Ltd., a biopharmaceutical company, develops, manufactures, and commercializes novel, bio-therapeutic, and non-surgical solutions for tissue repair and regeneration in United States, Europe, and internationally. It markets NexoBrid, a biopharmaceutical product for the removal of eschar, a dead or damaged tissue in adults with deep partial- and full-thickness thermal burns to burn centers and hospitals burn units. The company also develops EscharEx, which has completed Phase II clinical trials for the debridement of chronic and other hard-to-heal wounds; and MW005, which is in phase I/II for the treatment of low-risk basal cell carcinoma. MediWound Ltd. was incorporated in 2000 and is headquartered in Yavne, Israel.

About Dyne Therapeutics

Dyne Therapeutics, Inc., a clinical-stage muscle disease company, operates as a biotechnology company that focuses on advancing therapeutics for genetically driven muscle diseases in the United States. It is developing a portfolio of muscle disease therapeutics, including programs in myotonic dystrophy type 1; duchenne muscular dystrophy; and facioscapulohumeral dystrophy, as well as rare skeletal muscle, and cardiac and metabolic muscle diseases using its FORCE platform that delivers disease-modifying therapeutics. Dyne Therapeutics, Inc. was incorporated in 2017 and is headquartered in Waltham, Massachusetts.